Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-11.27%
0%
-11.27%
6 Months
173.4%
0%
173.4%
1 Year
173.83%
0%
173.83%
2 Years
153.99%
0%
153.99%
3 Years
92.58%
0%
92.58%
4 Years
26.99%
0%
26.99%
5 Years
309.46%
0%
309.46%
ABIONYX Pharma SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
39.75%
EBIT Growth (5y)
-184.75%
EBIT to Interest (avg)
-5.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.24
Sales to Capital Employed (avg)
0.39
Tax Ratio
19.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
22.26
EV to EBIT
-19.96
EV to EBITDA
-21.90
EV to Capital Employed
24.02
EV to Sales
27.76
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-120.36%
ROE (Latest)
-84.95%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'23
Dec'23
Dec'22
Change(%)
Net Sales
4.60
5.30
-13.21%
Operating Profit (PBDIT) excl Other Income
-3.50
-5.00
30.00%
Interest
0.30
0.20
50.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.50
-4.20
16.67%
Operating Profit Margin (Excl OI)
-760.90%
-1,064.00%
30.31%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2023 is -13.21% vs 657.14% in Dec 2022
Consolidated Net Profit
YoY Growth in year ended Dec 2023 is 16.67% vs 27.59% in Dec 2022
About ABIONYX Pharma SA 
ABIONYX Pharma SA
Pharmaceuticals & Biotechnology
Abionyx Pharma SA, formerly known as Cerenis Therapeutics Holding SA, is a France-based multinational biopharmaceutical company primarily engaged in the research, development and commercialization of High-density Lipoprotein (HDL) therapies for the treatment of cardiovascular and metabolic diseases. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The Company is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
Company Coordinates 
Company Details
Bat. D 33-43 Avenue Georges Pompidou , BALMA None : 31130
Registrar Details






